Drug intelligence / Profile preview

autologous dendritic cell vaccine (GEMCAD)

Development stage: Unknown
Lead developer: Grupo Cooperativo GEMCAD
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

The autologous dendritic cell vaccine developed by the Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD) is an individualized cancer immunotherapy biologic designed for the treatment of mismatch repair-proficient (MSS) metastatic colorectal cancer. The vaccine is produced by harvesting a patient's own dendritic cells and loading them with tumor-associated antigens. Once administered via intradermal injection, these professional antigen-presenting cells activate the patient's immune system, specifically cytotoxic T cells, to recognize and eliminate colorectal cancer cells. In clinical development, notably the GEMCAD 1602 trial (NCT03152565), this vaccine is evaluated in combination with the anti-PD-L1 antibody avelumab to enhance anti-tumor efficacy in pre-treated patients.

Other names: ADC vaccineGEMCAD autologous dendritic cell vaccineautologous dendritic cell vaccine-Grupo Espanol Multidisciplinario del Cancer Digestivo-colorectal cancer

Beyond the preview

Go deeper on autologous dendritic cell vaccine (GEMCAD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous dendritic cell vaccine (GEMCAD).

Explore the full profile